| Nov 4 |
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 3 |
Aquestive Therapeutics Q3 2024 Earnings Preview
|
| Oct 25 |
Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study
|
| Oct 25 |
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American Colle...
|
| Oct 24 |
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
|
| Oct 21 |
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
|
| Oct 6 |
Hedge funds pile into healthcare stocks amid dip, Goldman Sachs says
|
| Sep 30 |
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
|
| Sep 27 |
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
|
| Sep 9 |
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
|
